Strategy to develop a new drug for treatment-resistant depression - Role of electroconvulsive stimuli and BDNF

Yakugaku Zasshi

Volumn 127, Issue 4, 2007, Pages 735-742

  Li, Bingjin ^a   Suemaru, Katsuya ^a,b   Kitamura, Yoshihisa ^c   Cui, Ranji ^a   Gomita, Yutaka ^c   Araki, Hiroaki ^a,b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Antidepressant; Brain derived neurotrophic factor (BDNF); Electrical convulsive shock; Hypothalamic pituitary adrenal (HPA) axis; Treatment resistant depression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN; IMIPRAMINE; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; ELECTROCONVULSIVE THERAPY; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LOCOMOTION; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RAT; REVIEW;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG DESIGN; ELECTROCONVULSIVE THERAPY; HIPPOCAMPUS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RATS;

EID: 34047219231     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.127.735     Document Type: Review

References (43)

1. Lecrubier Y., J. Clin. Psychiatry, 62, 4-9 (2001).
2. Sheline Y. I., Wang P. W., Gado M. H., Csernansky J. G., Vannier M. W., Proc. Natl. Acad. Sci. U.S.A., 93, 3908-3913 (1996).
3. Videbech P., Ravnkilde B., Am. J. Psychiatry, 161, 1957-1966 (2004).
4. Chen B., Dowlatshahi D., MacQueen G. M., Wang J. F., Young L. T., Biol. Psychiatry, 50, 260-265 (2001).
5. Carroll B. J., Curtis G. C., Aust. N. Z. J. Psychiatry, 10, 13-20 (1976).
6. Heuser I., Yassouridis A., Holsboer F., J. Psychiatr. Res., 28, 341-356 (1994).
7. Kitamura Y., Araki H., Gomita Y., Pharmacol. Biochem. Behav., 71, 63-69 (2002).
8. Kitamura Y., Araki H., Suemaru K., Gomita Y., Pharmacol. Biochem. Behav., 72, 397-402 (2002).
9. Kitamura Y., Araki H., Shibata K., Gomita Y., Tanizaki Y., Eur. J. Pharmacol., 481, 5-77 (2003).
10. Paul S. M., Extein I., Calil H. M., Potter W. Z., Chodoff P., Goodwin F. K., Am. J. Psychiatry, 138, 486-489 (1981).
11. Pagnin D., de Queiroz V., Pini S., Cassano G. B., J. ECT., 20, 13-20 (2004).
12. Porsolt R. D., Bertin A., Jalfre M., Arch. Int. Pharmacodyn. Ther., 229, 327-336 (1977).
13. Danysz W., Kostowski W., Hauptmann M., Bidzinski A., Pol. J. Pharmacol. Pharm., 41, 15-22 (1989).
14. Scott E. K., Shiraya S. S., Pekary A. E., Sattin A., J. Psychiatr. Res., 38, 237-240 (2004).
15. Nibuya M., Morinobu S., Duman R., J. Neurosci., 15, 7539-7547 (1995).
16. Duman R. S., Vaidya V. A., J. ECT., 14, 181-193 (1998).
17. Altar C. A., Whitehead R. E., Chen R., Wortwein G., Madsen M. R., Biol. Psychiatry, 54, 703-709 (2003).
18. Altar C. A., Laeng P., Jurata L. W., Brockman J. A., Lemire A., Bullard J., Bukhman Y. V., Young T. A., Charles V., Palfreyman M. G., J. Neurosci., 24, 2667-2677 (2004).
19. Scott B. W., Wojtowicz J. M., Burnham W. M., Exp. Neurol., 165, 231-236 (2000).
20. Madsen T. M., Yeh D. D., Valentine G. W., Duman R. S., Neuropsychopharmacology, 30, 27-34 (2005).
21. Porsolt R. D., Bertin A., Jalfre M., Arch. Int. Pharmacodyn. Ther., 229, 327-336 (1977).
22. Kawakami Y., Kitamura Y., Araki H., Kitagawa K., Suemaru K., Shibata K., Gomita Y., Pharmacol. Biochem. Behav., 81, 65-70 (2005).
23. Bocchio-Chiavetto L., Zanardini R., Bortolomasi M., Abate M., Segala M., Giacopuzzi M., Andrea Riva M., Marchina E., Pasqualetti P., Perez J., Gennarelli M., Eur. Neuropsychopharmacol., 16, 620-624 (2006).
24. Artigas F., Perez V., Alvarez E., Arch. Gen. Psychiatry, 51, 248-251 (1994).
25. Blier P., Bergeron R., J. Clin. Psychopharmacol., 15, 217-222 (1995).
26. Katz M. M., Tekell J. L., Bowden C. L., Brannan S., Houston J. P., Berman N., Frazer A., Neuropsychopharmacology, 29, 566-579 (2004).
27. Keller M. B., J. Clin. Psychiatry, 17, 41-48 (1999).
28. Hirschfeld R. M., Acta Psychiatr. Scand. Suppl., 403, 35-38 (2000).
29. Weiner R. D., "Electroconvulsive Therapy, Section 31.7," Vol. II, Chap. 31, eds. by Kaplan H.I., Sadock B. J., Williams & Wilkins., Baltimore, London, 1989, pp. 1670-1680.
30. Pettinati H. M., Tamburello T. A., Ruetsch C. R., Psychopharmacol. (Bulletine), 30, 471 -475 (1994).
31. Li B., Suemaru K., Cui R., Kitamura Y., Gomita Y., Araki H., Eur. J. Pharmacol., 529, 114-121 (2006).
32. Hoshaw B. A., Malberg J. E., Lucki I., Brain Res., 1037, 204-208 (2005).
33. Shirayama Y., Chen A. C., Nakagawa S., Russell D. S., Duman R. S., J. Neurosci., 22, 3251-3261 (2002).
34. Naert G., Ixart G., Tapia-Arancibia L., Givalois L., Neuroscience, 139, 779-789 (2006).
35. Horger B. A., Iyasere C. A., Berhow M. T., Messer C. J., Nestler E. J., Taylor J. R., J. Neurosci., 19, 4110-4122 (1999).
36. Martin-Iverson M. T., Todd K. G., Altar C. A., J. Neurosci., 14, 1262-1270 (1994).
37. Narita M., Aoki K., Takagi M., Yajima Y., Suzuki T., Neuroscience, 119, 767-775 (2003).
38. Smith S. E., Sharp T., Psychopharmacology (Berlin), 133, 77-84 (1997).
39. Zarrindast M. R., Sahebgharani M., Burnham W. M., Eur. Neuropsychopharmacol., 14, 509 -514 (2004).
40. Duncan G. E., Breese G. R., Criswell H., Stumpf W. E., Mueller R. A., Covey J. B., J. Pharmacol. Exp. Ther., 238, 758-762 (1986).
41. Kawashima K., Araki H., Uchiyama Y., Aihara H., Eur. J. Pharmacol., 141, 1-6 (1987).
42. Dremencov E., Gur E., Lerer B., Newman M. E., Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 729-739 (2003).
43. Plaznik A., Kostowski W., Eur. J. Pharmacol., 135, 389-396 (1987).